Two years after completing proof-of-concept experiments for its IDBEST technology, Target Discovery has formed collaborations with the MD Anderson Cancer Center and the Eastern Virginia Medical School to develop protein isoform-based diagnostics for breast, prostate and ovarian cancer.

The Palo Alto, Calif.-based company is currently picking a list of biomarkers that will be examined for isoform differences. Researchers will then whittle down the markers to two or three promising isoforms on which to perform a larger validation study.